Equities

Sun Pharma Advanced Research Co Ltd

Sun Pharma Advanced Research Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)218.41
  • Today's Change-0.09 / -0.04%
  • Shares traded306.46k
  • 1 Year change-5.86%
  • Beta1.5692
Data delayed at least 15 minutes, as of Sep 20 2024 11:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1,5714,066157
Total Receivables, Net1,060439519
Total Inventory151111
Prepaid expenses483325
Other current assets, total--0.020.02
Total current assets2,6944,550712
Property, plant & equipment, net1,0861,073951
Goodwill, net------
Intangibles, net427255231
Long term investments--274232
Note receivable - long term922643674
Other long term assets4.69----
Total assets5,1508,3012,801
LIABILITIES
Accounts payable1,4231,483722
Accrued expenses25205.72
Notes payable/short-term debt4700.510
Current portion long-term debt/capital leases3530768
Other current liabilities, total471276219
Total current liabilities2,6511,7891,714
Total long term debt10712624
Total debt612157792
Deferred income tax------
Minority interest------
Other liabilities, total1,1361,258750
Total liabilities3,8933,1742,489
SHAREHOLDERS EQUITY
Common stock325325272
Additional paid-in capital20,38220,38213,406
Retained earnings (accumulated deficit)(19449)(15578)(13366)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.07----
Total equity1,2585,128312
Total liabilities & shareholders' equity5,1508,3012,801
Total common shares outstanding325325272
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.